Off-White to Pale-Beige Solid
anti-estrogen, anti-hyperlipoproteinemic, reduces bone loss
A Tamoxifen (T006000) derivative with antitumor effect on estrogen-dependent breast cancer cells.
A Tamoxifen derivative with antitumor effect on estrogen-dependent breast cancer cells
ChEBI: Droloxifene is a stilbenoid.
Droloxifene (5-20 mg/kg; p.o.; daily for 4 weeks) increases BMD of DFM at 10mg/kg, and completely prevents the decrease of BMC and BMD of DFM induced by ovariectomized (OVX) at 20 mg/kg/day[3].
| Animal Model: | 5-month-old sham-operate rats[3] |
| Dosage: | 5, 10, 20 mg/kg |
| Administration: | Oral; daily for 4 weeks |
| Result: | BMD of DFM increased significantly at 10mg/kg; completely prevented the decrease of BMC and BMD of DFM induced by OVX at 20 mg/kg/day.
|
